135 related articles for article (PubMed ID: 25757613)
1. Gene therapies for hepatitis C virus.
Verstegen MM; Pan Q; van der Laan LJ
Adv Exp Med Biol; 2015; 848():1-29. PubMed ID: 25757613
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
5. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
7. Telaprevir: changing the standard of care of chronic hepatitis C.
Rajani AK; Ravindra BK; Dkhar SA
J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
Cento V; Di Paolo D; Di Carlo D; Micheli V; Tontodonati M; De Leonardis F; Aragri M; Antonucci FP; Di Maio VC; Mancon A; Lenci I; Manunta A; Taliani G; Di Biagio A; Nicolini LA; Nosotti L; Sarrecchia C; Siciliano M; Landonio S; Pellicelli A; Gasbarrini A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F
Dig Liver Dis; 2015 Feb; 47(2):157-63. PubMed ID: 25544656
[TBL] [Abstract][Full Text] [Related]
9. [Chronic hepatitis C infection--eradication of the virus].
Ben Ari Z
Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
[TBL] [Abstract][Full Text] [Related]
10. [Novel methods of hepatitis C treatment and prevention].
Chmielewska AM; Rychłowska M; Król E; Solarz K; Bieńkowska-Szewczyk K
Postepy Hig Med Dosw (Online); 2015 Aug; 69():946-63. PubMed ID: 26400881
[TBL] [Abstract][Full Text] [Related]
11. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.
Macartney MJ; Irish D; Bridge SH; Garcia-Diaz A; Booth CL; McCormick AL; Labbett W; Smith C; Velazquez C; Tanwar S; Trembling P; Jacobs M; Dusheiko G; Rosenberg W; Haque T
Antiviral Res; 2014 May; 105():112-7. PubMed ID: 24594347
[TBL] [Abstract][Full Text] [Related]
12. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
[TBL] [Abstract][Full Text] [Related]
13. [Hepatitis C virus: 25 years-old, the end?].
Pol S
Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
[TBL] [Abstract][Full Text] [Related]
14. Telaprevir for the treatment of hepatitis C.
Forestier N; Zeuzem S
Expert Opin Pharmacother; 2012 Mar; 13(4):593-606. PubMed ID: 22332992
[TBL] [Abstract][Full Text] [Related]
15. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
[TBL] [Abstract][Full Text] [Related]
16. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
Wyles DL; Gutierrez JA
J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic approaches for hepatitis C.
Au JS; Pockros PJ
Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
19. Optimizing treatment in HIV/HCV coinfection.
Puoti M; Rossotti R; Travi G; Panzeri C; Morreale M; Chiari E; Cocca G; Orso M; Moioli MC
Dig Liver Dis; 2013 Sep; 45 Suppl 5():S355-62. PubMed ID: 24091116
[TBL] [Abstract][Full Text] [Related]
20. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus.
Ely A; Arbuthnot P
Discov Med; 2015 Sep; 20(109):137-43. PubMed ID: 26463095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
